Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

Current Medical Research and Opinion

Volumn 29, Issue 8, 2013, Pages 989-1000

  Gauthier, Serge ^a   Robillard, Alain ^b   Cohen, Sharon ^c   Black, Sandra ^d   Sampalis, John ^b,e,f   Colizza, Diane ^g   De Takacsy, Frederica ^g   Schecter, Robyn ^g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Toronto Memory Program   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^g Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

Alzheimer's; Effectiveness; Rivastigmine transdermal patch; Tolerability

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ANOREXIA; APPLICATION SITE ERYTHEMA; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; PROSPECTIVE STUDY; PRURITUS; RASH; SKIN MANIFESTATION; TRANSDERMAL PATCH; VOMITING;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880504446     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.802230     Document Type: Article

References (62)

1. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL (eds). Alzheimer's Disease. New York: Raven Press, 1994:263-91
2. Martin BC, Ricci JF, Kotzan JA, et al. The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord 2000;14:151-9
3. Sloan FA, Taylor Jr DH. Effect of Alzheimer disease on the cost of treating other diseases. Alzheimer Dis Assoc Disord 2002;16:137-43 (Pubitemid 35001088)
4. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
5. Alzheimer's Association. 2011 Alzheimer's Disease Facts and Figures. 7. Alzheimer's Association, 2011
6. Alzheimer Society Canada. Rising Tide: The Impact of Dementia on Canadian Society. Available at: Http://www.alzheimer.ca/en/Get-involved/Raise-yourvoice/ Rising-Tide [Last accessed 4 February 2013]
7. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131-8 (Pubitemid 37271383)
8. Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit. J Neural Transm 2002;109:1053-65 (Pubitemid 34762344)
9. Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93 (Pubitemid 34174568)
10. Darvesh S, Hopkins D. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003;463: 25-43 (Pubitemid 36835411)
11. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-7 (Pubitemid 30179175)
12. Bullock R, Touchon J, Bergman J, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27 (Pubitemid 41140736)
13. Gauthier S, Juby A, Morelli L, et al EXTEND Investigators. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: The EXTEND study. Curr Med Res Opin 2006;22:2251-65
14. Tekin S, Fairbanks LA, O'Connor S, et al. Activities of daily living in Alzheimer's disease: Neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 2001;9:81-6 (Pubitemid 32062077)
15. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-22 (Pubitemid 32217458)
16. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-38 (Pubitemid 34665750)
17. Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005;19:189-95 (Pubitemid 40522806)
18. Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: The relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004;21:453-78 (Pubitemid 38736890)
19. Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004;20:1747-52 (Pubitemid 39611933)
20. Mossello E, Tonon E, Caleri V, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: A 'real world' study. Arch Gerontol Geriatr Suppl 2004;38:297-307 (Pubitemid 38822879)
21. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010;64:651-60
22. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67 (Pubitemid 46831690)
23. Winblad B, Grossberg G, Frolich L, et al. IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69(4 Suppl 1):S14-22 (Pubitemid 47205655)
24. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: Potential benefits of a transdermal patch. Curr Med Res Opin 2007;23:2705-13 (Pubitemid 350146408)
25. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-91 (Pubitemid 46831693)
26. Nagy B, Brennan A, Brandtmuller A, et al. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry 2011;26: 483-94
27. Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol Assess 2012;16:1-470
28. Alva G, Grossberg GT, Schmitt FA, et al. Efficacy of rivastigmine transdermal patch on activities of daily living: Item responder analyses. Int J Geriatr Psychiatry 2011;26:356-63
29. Articus K, Baier M, Tracik F, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract 2011;65:790-6
30. Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallelgroup, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:341-53
31. Farlow MR, Grossberg G, Gauthier S, et al. The ACTION study: Methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin 2010;26:2441-7
32. Grossberg G, Sadowsky C, Frostl H, et al. Safety and tolerability of the rivastigmine patch: Results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-64
33. Nakamura Y, Imai Y, Shigeta M, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2011;1:163-79
34. Sadowsky CH, Farlow MR, Meng X, et al. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: Data from three clinical trials. Int J Clin Pract 2010;64:188-93
35. Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: A multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011;27:1375-83
36. Dhillon S. Rivastigmine transdermal patch: A review of its use in the management of dementia of the Alzheimer's type. Drugs 2011;71:1209-31
37. Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-tomoderate Alzheimer's disease: A post hoc analysis. Curr Med Res Opin 2010;26:263-9
38. Molloy DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry 1991;148:102-5
39. Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician 2001;47:2018-23
40. Qaseem A, Snow V, Cross Jr JT, et al. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370-8 (Pubitemid 351665468)
41. Kupper LL, Hafner KB. How appropriate are popular sample size formulas? Am Statistician 1989;43:101-5
42. Grossberg G, Meng X, Olin JT. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011;26:65-71
43. Sadowsky C, Perez JA, Bouchard RW, et al. Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. CNS Neurosci Ther 2010;16:51-60
44. Sadowsky CH, Dengiz A, Meng X, et al; US38 Study Group. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20- week extension phase results. Prim Care Companion J Clin Psychiatry 2010;2:e1-e8
45. Seibert J, Tracik F, Articus K, et al. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatr Dis Treat 2012;8:141-7
46. Wattmo C, Wallin AK, Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. BMC Neurol 2012;2:134
47. Gauthier S, Juby A, Rehel B, et al. EXACT: Rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract 2007;61:886-95 (Pubitemid 46744076)
48. Gauthier S, Juby A, Dalziel W, et al; EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Curr Med Res Opin 2010;26:1149-60
49. Pregelj P. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. Psychogeriatrics 2012;12:165-71
50. Minthon L, Wallin AK, Eriksson S, et al. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand 2009;119:180-5
51. Tian H, Abouzaid S, Chen W, et al. Patient adherence to transdermal rivastigmine after switching from oral donepezil: A retrospective claims database study. Alzheimer Dis Assoc Disord 2012;[Epub ahead of print. 2012 Aug 12.]
52. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995;56(Suppl 1):18-22
53. Alzheimer's Association and National Alliance for Caregiving. National Survey. 2004
54. Slattum PW, Johnson MA. Caregiver burden in Alzheimer's disease. Consult Pharm 2004;19:352-62 (Pubitemid 38500717)
55. Travis SS, Kao HF, Acton GJ. Helping family members manage medication administration hassles. J Psychosoc Nurs Ment Health Serv 2005;43:13-15 (Pubitemid 41704352)
56. McGraw C, Drennan V. Self-administration of medicine and older people. Nurs Stand 2001;15:33-6
57. Ryan AA. Medication compliance and older people: A review of the literature. Int J Nurs Stud 1999;36:153-62
58. Sink KM, Covinsky KE, Barnes DE, et al. Caregiver characteristics are associated with neuropsychiatric symptoms of dementia. J Am Geriatr Soc 2006;54:796-803 (Pubitemid 44030202)
59. Cramer JA. Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. Am J Manag Care 1998;4:1563-8 (Pubitemid 28555518)
60. Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35 (Pubitemid 37076322)
61. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310 (Pubitemid 32804122)
62. Boada M, Arranz FJ. Transdermal is better than oral: Observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord 2013;35:23-33